Ovarian Cancer Stocks List



Recent Signals

Date Stock Signal Type
2021-04-09 ADAP 20 DMA Resistance Bearish
2021-04-09 ADAP Bollinger Band Squeeze Range Contraction
2021-04-09 ARAV 180 Bearish Setup Bearish Swing Setup
2021-04-09 AWH 180 Bearish Setup Bearish Swing Setup
2021-04-09 AWH Narrow Range Bar Range Contraction
2021-04-09 CASI NR7 Range Contraction
2021-04-09 CASI Narrow Range Bar Range Contraction
2021-04-09 CASI NR7-2 Range Contraction
2021-04-09 CLDX Doji - Bullish? Reversal
2021-04-09 CLDX Narrow Range Bar Range Contraction
2021-04-09 CTIC Hammer Candlestick Bullish
2021-04-09 CTIC Crossed Above 200 DMA Bullish
2021-04-09 CTIC Stochastic Buy Signal Bullish
2021-04-09 GENE Expansion Pivot Buy Setup Bullish Swing Setup
2021-04-09 GENE Crossed Above 20 DMA Bullish
2021-04-09 GENE Crossed Above 50 DMA Bullish
2021-04-09 GENE Volume Surge Other
2021-04-09 GENE Wide Range Bar Range Expansion
2021-04-09 GENE Shooting Star Candlestick Bearish
2021-04-09 GENE Lizard Bearish Bearish Day Trade Setup
2021-04-09 GENE Pocket Pivot Bullish Swing Setup
2021-04-09 HARP Shooting Star Candlestick Bearish
2021-04-09 HARP Pocket Pivot Bullish Swing Setup
2021-04-09 HARP Upper Bollinger Band Walk Strength
2021-04-09 HARP Stochastic Sell Signal Bearish
2021-04-09 HARP Doji - Bearish? Reversal
2021-04-09 HTBX Doji - Bearish? Reversal
2021-04-09 KZIA Upper Bollinger Band Walk Strength
2021-04-09 KZIA Slingshot Bullish Bullish Swing Setup
2021-04-09 MRKR Stochastic Reached Oversold Weakness
2021-04-09 MRKR NR7 Range Contraction
2021-04-09 MRKR Narrow Range Bar Range Contraction
2021-04-09 MRUS Fell Below 50 DMA Bearish
2021-04-09 MRUS Stochastic Reached Overbought Strength
2021-04-09 MRUS Narrow Range Bar Range Contraction
2021-04-09 MRUS NR7-2 Range Contraction
2021-04-09 MRUS NR7 Range Contraction
2021-04-09 MYGN NR7 Range Contraction
2021-04-09 MYGN Narrow Range Bar Range Contraction
2021-04-09 MYGN Stochastic Reached Oversold Weakness
2021-04-09 MYGN MACD Bearish Centerline Cross Bearish
2021-04-09 NVCR Hammer Candlestick Bullish
2021-04-09 NVCR NR7 Range Contraction
2021-04-09 NVCR Narrow Range Bar Range Contraction
2021-04-09 NXTC Narrow Range Bar Range Contraction
2021-04-09 POAI Crossed Above 50 DMA Bullish
2021-04-09 POAI Pocket Pivot Bullish Swing Setup
2021-04-09 SLRX Narrow Range Bar Range Contraction
2021-04-09 SLRX NR7 Range Contraction
2021-04-09 SLS 50 DMA Support Bullish
2021-04-09 SLS Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-04-09 SLS 20 DMA Resistance Bearish
2021-04-09 STTK Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-09 STTK Spinning Top Other
2021-04-09 STTK 1,2,3 Retracement Bearish Bearish Swing Setup
2021-04-09 STTK MACD Bullish Signal Line Cross Bullish
2021-04-09 VBLT MACD Bearish Signal Line Cross Bearish
2021-04-09 VERU Hammer Candlestick Bullish
2021-04-09 VERU NR7 Range Contraction
2021-04-09 VERU Narrow Range Bar Range Contraction
2021-04-09 VERU Lizard Bullish Bullish Day Trade Setup
2021-04-09 VERU NR7-2 Range Contraction
2021-04-09 VSTM Upper Bollinger Band Walk Strength
2021-04-09 VSTM NR7 Range Contraction
2021-04-09 VSTM Non-ADX 1,2,3,4 Bullish Bullish Swing Setup

Recent News for Ovarian Cancer Stocks

Date Stock Title
Apr 9 NKTR Sanofi confirms partial response for cancer therapy in mid-stage study
Apr 9 GENE Genetic technologies shares rise after update on COVID-19 risk test launch
Apr 9 GENE Genetic Technologies Provides Update on COVID-19 Risk Test Launch
Apr 9 VSTM Verastem: New Assets, New Indications
Apr 9 VBLT Vascular Biogenics prices $25M stock offering
Apr 9 MYGN 3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19
Apr 9 VBLT Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
Apr 9 NVCR Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
Apr 9 VBLT The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Apr 8 VBLT Vascular Biogenics proposes capital raise
Apr 8 VBLT Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Apr 8 MRKR Study shows wearables could detect COVID-19 earlier
Apr 8 PSTV Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021
Apr 8 TCRR TCR² Therapeutics to Present at the Needham Healthcare Conference
Apr 7 MRKR Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't?
Apr 7 NVCR NovoCure: An Underfollowed Gem
Apr 7 CTIC CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14
Apr 7 ADAP What Type Of Shareholders Own The Most Number of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares?
Apr 6 CLDX ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
Apr 6 STTK Shattuck Labs Announces Participation in Needham’s 20th Annual Healthcare Conference

Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. These symptoms may include bloating, pelvic pain, abdominal swelling, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver.The risk of ovarian cancer increases in women who have ovulated more over their lifetime. This includes those who have never had children, those who begin ovulation at a younger age and those who reach menopause at an older age. Other risk factors include hormone therapy after menopause, fertility medication, and obesity. Factors that decrease risk include hormonal birth control, tubal ligation, and breast feeding. About 10% of cases are related to inherited genetic risk; women with mutations in the genes BRCA1 or BRCA2 have about a 50% chance of developing the disease. The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma. There are five main subtypes of ovarian carcinoma, of which high-grade serous carcinoma is the most common. These tumors are believed to start in the cells covering the ovaries, though some may form at the Fallopian tubes. Less common types of ovarian cancer include germ cell tumors and sex cord stromal tumors. A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery.Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks. Those at very high risk may have their ovaries removed as a preventive measure. If caught and treated in an early stage, ovarian cancer is often curable. Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Outcomes depend on the extent of the disease, the subtype of cancer present, and other medical conditions. The overall five-year survival rate in the United States is 45%. Outcomes are worse in the developing world.In 2012, new cases occurred in 239,000 women. In 2015 it was present in 1.2 million women and resulted in 161,100 deaths worldwide. Among women it is the seventh-most common cancer and the eighth-most common cause of death from cancer. The typical age of diagnosis is 63. Death from ovarian cancer is more common in North America and Europe than in Africa and Asia.

More about Ovarian Cancer
Browse All Tags